Crossmark

First-line chemotherapy for mCRC—a review and evidence-based algorithm

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2015.129

Published Online: 2015-07-28

Published Print: 2015-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cremolini, Chiara

Schirripa, Marta

Antoniotti, Carlotta

Moretto, Roberto

Salvatore, Lisa

Masi, Gianluca

Falcone, Alfredo

Loupakis, Fotios
License Information

Text and Data Mining valid from 2015-07-28
More Information

Article History

First Online: 28 July 2015

Competing interests

: C.C. has received payment for consultancy and honouraria for speaking from Amgen, Bayer, and Roche. G.M. has received payment for consultancy and honouraria for speaking from Amgen, Bayer, Merck and Roche. A.F. and F.L. have received payment for consultancy and honouraria for speaking from Amgen, Bayer, Merck, Roche, and Sanofi. The other authors declare no competing interests.